Chong Kun Dang Pharmaceutical KRX:185750KOSPI

종근당 · Korean news coverage and regulatory filings, organized.

Articles, 24h21
Articles, 7 days74
DART filings, 7 days0
Articles tracked74since Sep 11

In Q2 2026, Chong Kun Dang Pharmaceutical reported revenue of ₩478bn, up 10.0% year on year, and operating profit of ₩18.6bn. Chong Kun Dang Pharmaceutical (종근당) appeared in 74 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 14 with 51 articles. It was most often mentioned alongside OliX Pharmaceuticals, Hanmi Pharm and Cell Biotech.

Chong Kun Dang Pharmaceutical quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩478bn+10.0%₩18.6bn₩20.4bn
Q1 2026₩448bn+11.7%₩14.1bn₩12.6bn
Q4 2025 derived₩427bn+2.7%₩23.5bn₩26.3bn
Q3 2025₩430bn+4.1%₩21.0bn₩20.2bn
Q2 2025₩435bn+9.6%₩23.6bn₩19.4bn
Q1 2025₩401bn+10.9%₩12.5bn₩11.9bn
Q4 2024 derived₩415bn-17.7%₩6.8bn₩8.1bn
Q3 2024₩413bn+2.3%₩26.0bn₩21.7bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.

Chong Kun Dang Pharmaceutical top stories 2 weeks, by number of outlets

  1. 1
    종근당, ‘발효침향 프리미엄 60환’ 리뉴얼 출시
    30 outlets · 30 articlesFirst report Sep 14 09:15 더바이오
  2. 2
    경기경제청, 시흥배곧지구 종근당 지식산업센터 건립 의결
    8 outlets · 8 articlesFirst report Sep 13 07:01 연합뉴스경제
  3. 3
  4. 4
    종근당, 추석 앞두고 ‘발효침향 프리미엄 60환’ 리뉴얼…침향 함량 25% 확대
    3 outlets · 3 articlesFirst report Sep 14 09:47 파이낸셜투데이
  5. 5
    종근당, 시흥 배곧 2.2조 지식산업센터 '조건부 통과'…2028년 가동 목표
    2 outlets · 2 articlesFirst report Sep 14 13:48 알파경제
  6. 6
    시흥 배곧에 종근당 지식산업센터 건립…2조2000억원 투자
    2 outlets · 2 articlesFirst report Sep 13 13:01 신아일보

Latest Chong Kun Dang Pharmaceutical news Korean headlines